Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Vanda Pharmaceuticals Gained as Much as 11.1% Today

By Maxx Chatsko – Updated Apr 19, 2019 at 10:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharma company reported fourth-quarter and full-year 2018 operating results.

What happened

Shares of Vanda Pharmaceuticals (VNDA -1.45%) rose over 11% today after the company reported fourth-quarter and full-year 2018 financial results. The jump higher is welcomed by shareholders, who have seen the stock plunge lower in recent weeks after the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on a promising drug candidate looking to enter late-stage clinical trials.

Today's share movement isn't entirely unexpected. The recent slide had appeared a bit overdone, especially considering that Vanda Pharmaceuticals turned profitable through the first nine months of 2018. That significantly de-risked the development of its pipeline, even in light of the partial clinical hold from overly cautious regulators. Full-year 2018 results only strengthened that argument.

As of 2:57 p.m. EST, the stock had settled to an 8.7% gain.

An ascending stock chart on a display.

Image source: Getty Images.

So what

Vanda Pharmaceuticals reported fourth-quarter 2018 operating income of $9.1 million, which represented 42% of the full-year total of $21.7 million. The business achieved improving financial health on the heels of growing sales of the Hetlioz franchise, a medication approved for a rare sleep disorder, and falling operating expenses.

Here's how full-year 2018 results stack up against 2017:

Metric

2018

2017

Year-Over-Year Change

Hetlioz revenue

$115.8 million

$89.9 million

29%

Total revenue

$193.1 million

$165.1 million

17%

Operating expenses

$171.4 million

$181.9 million

(6%)

Operating income

$21.7 million

($16.9 million)

N/A

Net income

$25.1 million

($15.6 million)

N/A

Data source: Press release.

Management expects the momentum to continue in the year ahead. Vanda Pharmaceuticals has prepared investors to expect full-year 2019 revenue in the neighborhood of $220 million, which includes Hetlioz revenue of approximately $140 million.

The business didn't provide guidance for operating income, but it's likely to trend upward, as well. If the fourth-quarter 2018 operating margin of 17% is achieved throughout the current fiscal year and revenue guidance of $220 million is met, then the business would achieve operating income of $38 million in 2019. That would mark a year-over-year increase of 75% -- and it's likely to be an underestimate considering operating margin has steadily improved each quarter in recent years.

The $1 billion company expects to end 2019 with over $260 million in cash on the balance sheet.

Check out the latest Vanda Pharmaceuticals earnings call transcript.

Now what

Investors will now be watching developments regarding the ongoing dispute with the FDA and the partial clinical hold slapped onto the company's promising drug candidate. As of right now, Vanda Pharmaceuticals doesn't expect the regulatory hurdle to delay the timeline for ongoing or planned clinical trials or the potential filing of a new drug application down the road.

That's good news, although a comfortably profitable business makes the closely watched developments a little less important than Wall Street has made them out to be.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vanda Pharmaceuticals Inc. Stock Quote
Vanda Pharmaceuticals Inc.
VNDA
$9.53 (-1.45%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.